These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 19318598

  • 21. Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.
    Derman R, Kohles JD, Babbitt A.
    Clin Interv Aging; 2009; 4():357-65. PubMed ID: 19851511
    [Abstract] [Full Text] [Related]

  • 22. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS, Min YK, Kang MI, Chung DJ, Kim YK, Choi WH, Shong MH, Park JH, Byun DW, Yoon HK, Shin CS, Lee YS, Kwon NH.
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
    Iwamoto J, Okano H, Furuya T, Urano T, Hasegawa M, Hirabayashi H, Kumakubo T, Makita K.
    J Bone Miner Metab; 2016 Mar; 34(2):201-8. PubMed ID: 25794468
    [Abstract] [Full Text] [Related]

  • 26. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R.
    Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
    [Abstract] [Full Text] [Related]

  • 27. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E, Lang A, Robbins S, Ström O.
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [Abstract] [Full Text] [Related]

  • 28. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
    Adami S, Pavelka K, Cline GA, Hosterman MA, Barton IP, Cohen SB, Bensen WG.
    Mayo Clin Proc; 2005 Oct; 80(10):1278-85. PubMed ID: 16212139
    [Abstract] [Full Text] [Related]

  • 34. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.
    Ettinger MP, Felsenberg D, Harris ST, Wasnich R, Skag A, Hiltbrunner V, Wilson K, Schimmer RC, Miller PD.
    J Rheumatol; 2005 Oct; 32(10):1968-74. PubMed ID: 16206354
    [Abstract] [Full Text] [Related]

  • 37. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population.
    Modi A, Siris S, Yang X, Fan CP, Sajjan S.
    J Manag Care Spec Pharm; 2015 Jun; 21(6):499-506. PubMed ID: 26011551
    [Abstract] [Full Text] [Related]

  • 38. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O, Kindundu CM, Barbeau M, LeLorier J.
    Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R.
    J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.